Our goal is to provide information on the latest advances in prostate cancer treatment and information on the research and work of Dr. William J. Catalona, Medical Director of the Urological Research Foundation (URF).
Dr. Catalona developed the PSA test as a screening test for prostate cancer. He and his research collaborators continue their important work.
The funds and energies of the Urological Research Foundation (URF) are directed to research for the prevention, detection, treatment and cure of the diseases of the prostate and most specifically, prostate cancer.
Dr. Catalona is one of the first surgeons to perform and perfect nerve sparing surgery in radical prostatectomy operations. Dr. Catalona has performed more than 6,000 radical prostatectomies.
Early Treatment of Prostate Cancer
The Early Treatment of Prostate Cancer video explains the issues associated with the treatment of early prostate cancer. This video is for men who have been recently diagnosed with prostate cancer and are trying to weigh the various treatment options.
Watch the video.
Winter 2014 QUEST
The publication of Dr. Catalona and the Urological Research Foundation
The issue addresses the following topics:
All QUEST material is under copyright and cannot be duplicated for any reason other than personal use.
- Past issues of QUEST are here.
- QUEST articles from past issues are here.
- Subscribe to QUEST here.
- Search QUEST articles using the search box at the top of the page.
SPORE: Making Strides in Prostate Cancer Research
Dr. Catalona and his colleagues submitted a new grant application for the Specialized Programs of Research Excellence (SPORE) in Prostate Cancer. Learn more about the research projects in the Winter 2014 issue of QUEST. SPOREs are an integral part of the National Cancer Instituteís efforts to promote collaborative and interdisciplinary cancer research.
Dr. Catalona and the University of Chicago researchers who collaborate on the SPORE project at the Prostate Cancer Foundation Scientific Retreat. (left to right) William J. Catalona, MD; Geoffrey Greene, PhD; Donald Vander Griend, PhD; Suzanne Conzen, MD, PhD; Walter Stadler, MD; David Vander Wheele, MD, PhD; Russell Szmulewitz, MD; Stan Liauw, MD, PhD.
WGN News Features PHI Test
The Prostate Health Index (PHI) test is now available at Northwestern Memorial Hospital, offering patients a new option for detecting prostate cancer. In February, WGN News highlighted the PHI test and interviewed Dr. Catalona in a story entitled “New test means new way to fight prostate cancer.”
Watch the WGN feature story here.
Alert: New Concerns Revealed about Robotic Surgery
FDA Surveying Hospitals and Surgeons about Robotic Surgery Complications
The FDA is investigating the safety of surgical robots used in many US hospitals for surgery. By surveying surgeons at key hospitals, the government agency seeks to determine if the rise in incidents, including deaths, reported to the FDA result from the robots or from other issues.
Growing Concerns About Surgical Robots
A CNBC Investigations, Inc. review reveals a rise in lawsuits and complaints about injuries after da Vinci surgical robot procedures.
- Robot Doctors in the Operating Room (ABC News, April 12, 2013)
- Robotic Surgery: Growing Sales, but Growing Concerns (CNBC, March 19, 2013)
- Intuitive Surgical: Angel with Broken Wings, or the Devil in Disguise? (Citron Research, January 17, 2013)
- Has the Halo been Broken on Intuitive Surgical? (Citron Research, December 19, 2012)
Relevant QUEST Articles:
Cancer Detection Tool Saves Lives
The Large Urology Group Practice Association (LUGPA) released its prostate cancer screening guidelines in response to the recent PSA controversy, saying that data clearly demonstrates that are detecting prostate cancer earlier and thus saving lives.
The LUGPA's position on PSA screening is:
- Risks of prostate cancer screening must be uncoupled from risks of prostate cancer detection and treatment
- PSA testing facilitates the early detection of prostate cancer, which results in a reduced risk of being diagnosed with or developing locally advanced and/or metastatic prostate cancer, and a reduction in prostate cancer-specific mortality
- A baseline PSA level should be obtained in men in their 40s who have made an informed decision to pursue early detection of prostate cancer
- Intervals for an individual's prostate cancer screening should be adapted to: baseline PSA, prostate cancer risk factors (including African-American heritage and a family history of prostate cancer), and the potentially short preclinical timeline of aggressive cancers
- PSA screening should be offered to men with a life expectancy of greater than or equal to 10 years, regardless of age
- PSA testing should not be considered on its own, but rather as part of a multivariable approach to early prostate cancer detection
LUGPA is an organization advocating for integrated and coordinated urological care with more than 2,000 physician experts across the U.S. The association represents 121 large urology group practices in the United States, with more than 2,000 physicians who make up more than 20% of the nationís practicing urologists.
International Prostate Cancer Research Group Receives Funding
The International Consortium for Prostate Cancer Genetics (ICPCG) received a grant for its important genetic research. Specifically, the ICPCG whole exome sequence project will receive funding. The results of this project could be incorporated in Dr. Catalonaís SPORE (Specialized Program of Research Excellence) proposal to discover genetic variants associated with the aggressive types of prostate cancer that lead to the failure of active surveillance.
The ICPCG is a collaborative group conducting research on familial prostate cancer. The researchers in this group share a common interest in genetic susceptibility for prostate cancer. Dr. Catalona is a principal investigator of the Northwestern University site of the ICPCG.
Learn more about the ICPCG here.
Responding to USPSTF Recommendation
© photo by Dan Oldfield
Not all things that look alike behave alike.
Click to see articles and material.
This section includes articles to help you understand the disturbing ramifications of the recent USPSTF recommendation on PSA testing, the misinterpretation of studies, and what can be done to ensure men have a choice in taking the test. We also provide information on contacting your government representatives.
"PSA is the best screening test we have for prostate cancer, and until there is a replacement for PSA, it would be unconscionable to stop it. Contrary to the USPSTF report, compelling evidence shows that PSA screening reduces prostate cancer deaths. This evidence needs to be shared with the public."
Healthcare decisions are as much about the future as the present, and they need to be based upon accurate and reliable information.
Participate in Research Studies
Northwestern Memorial Hospital and Dr. William Catalona offer opportunities for you to participate in research projects on the treatment and prevention of prostate cancer.
Learn more here.
Dr. Catalona: Over 6,000 Operations
Dr. Catalona is celebrating a surgical anniversary. He has now performed more than 6,000 radical prostatectomies, more than anyone else in the world. Dr. Catalona is one of the first surgeons to perform and perfect nerve- sparing surgery in radical prostatectomy operations. His patients have come from all 50 states in the United States, as well as from Asia, Europe, the Middle East, and Central and South America.
High Ranking For Northwestern’s Department of Urology
The National Institutes of Health (NIH) ranks individual departments within medical schools. The Department of Urology ranked third nationally among urology departments.